Subject demographics and baseline characteristics compared among three antihypertensive groups
| Characteristics | Hydralazine (N=71) | Labetalol (N=415) | Nicardipine (N=670) | P value |
| Age (years), median (Q1, Q3) | 59.0 (51, 76) | 58.0 (50, 70) | 58.0 (50, 69) | 0.542 |
| BMI, median (Q1, Q3) | 28.3 (23.8, 34.0) | 29.3 (24.7, 34.4) | 28.3 (24.7, 32.9) | 0.359 |
| Dose (mg), median (Q1, Q3) | 10.0 (10.0, 10.0) | 17.5 (10.0, 20.0) | 2.0 (0.7, 5) | ------ |
| Latency between antihypertensive administration and blood pressure measurement (minutes), median (Q1, Q3) | 13.0 (8.0, 25.0) | 13.0 (6.0, 25.0) | 13.0 (5.0, 25.0) | 0.555 |
| Female gender, n (%) | 24 (33.8) | 171 (41.2) | 283 (42.2) | 0.389 |
| Pre-ICH mRS >3, n (%) | 0 (0) | 7 (1.7) | 17 (2.6) | 0.281 |
| History of stroke, n (%) | 12 (16.9) | 75 (18.3) | 101 (15.2) | 0.411 |
| History of hypertension, n (%) | 63 (88.7) | 354 (86.1) | 580 (87.5) | 0.742 |
| History of diabetes, n (%) | 27 (38.6) | 107 (26.4) | 174 (26.4) | 0.087 |
| Cigarette use ever, n (%) | 36 (54.5) | 180 (47.8) | 264 (45.1) | 0.296 |
| Heavy alcohol use, n (%) | 15 (23.1) | 64 (16.4) | 97 (15.3) | 0.265 |
| Cocaine/crack use, n (%) | 3 (4.4) | 37 (9.9) | 56 (9.1) | 0.340 |
Race/ethnicity, n (%)
| 20 (28.2) 26 (36.6) 25 (35.2) | 168 (40.5) 129 (31.1) 118 (28.4) | 270 (40.3) 235 (35.1) 165 (24.6) | 0.117 |
| Lobar location, n (%) | 21 (29.6) | 107 (26.0) | 155 (23.4) | 0.382 |
| Haematoma volume (mL) median (Q1, Q3) | 17.8 (2.8, 32.8) | 20.9 (6.2, 35.6) | 15.3 (3.5, 27.1) | 0.451 |
| Prior antihypertensive use, n (%) | 41 (57.8) | 225 (54.2) | 329 (49.1) | 0.144 |
| Initial SBP (mm Hg), mdian (Q1, Q3) | 197.0 (181.0, 222.0) | 200.0 (181.0, 222.0) | 200.5 (178.0, 222.0) | 0.730 |
| Initial DBP (mm Hg), median (Q1, Q3) | 105.0 (91.0, 120.0) | 109.0 (94.0, 124.0) | 108.0 (93.0, 125.0) | 0.552 |
P value: Kruskal-Wallis test for continuous variables, χ2 test for categorical variables with significance set to <0.05. Antihypertensive doses were not compared and are provided as a reference for amounts used in this cohort.
BMI, body mass index; DBP, diastolic blood pressure; ICH, intracerebral haemorrhage; mRS, modified Rankin Scale; Q1, lower quartile; Q3, upper quartile; SBP, systolic blood pressure.